Hutchison China MediTech Limited’s (HCM) Buy Rating Reaffirmed at Beaufort Securities

Beaufort Securities reissued their buy rating on shares of Hutchison China MediTech Limited (LON:HCM) in a report released on Tuesday morning.

Separately, Panmure Gordon increased their target price on Hutchison China MediTech Limited from GBX 2,900 ($36.69) to GBX 3,530 ($44.66) and gave the stock a buy rating in a research note on Thursday, May 18th.

Hutchison China MediTech Limited (HCM) opened at 3510.00 on Tuesday. Hutchison China MediTech Limited has a 12 month low of GBX 1,760.00 and a 12 month high of GBX 3,520.00. The firm’s 50-day moving average is GBX 3,086.25 and its 200-day moving average is GBX 2,625.17. The stock’s market capitalization is GBX 2.13 billion.

ILLEGAL ACTIVITY WARNING: This piece was reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *